| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -10,168 | -14,662 | -14,441 | -25,545 |
| Prepaid expenses and other assets | NaN | NaN | 456 | -592 |
| Accounts payable | NaN | NaN | 725 | -732 |
| Depreciation and amortization note 3 | 57 | 57 | 54 | 117 |
| Stock-based compensation note 7, note 7 and note 7 | -685 | 1,301 | 2,340 | 5,120 |
| Shares issued as settlement with trade vendor | NaN | 0 | NaN | NaN |
| Accrued interest on svb convertible debt note 8 | NaN | 0 | NaN | NaN |
| Amortization of 2024 svb convertible term loan transaction costs note 6 | 12 | 11 | 13 | 28 |
| Change in fair value of contingent consideration note 4 and note 5 | -285 | 114 | 106 | 188 |
| Prepaid expenses and other assets-Nonrelated Party | -1,625 | 1,204 | NaN | NaN |
| Prepaid expenses and other assets-Related Party | -68 | 193 | NaN | NaN |
| Accounts payable-Nonrelated Party | -53 | -1,091 | NaN | NaN |
| Accounts payable-Related Party | 19 | 8 | NaN | NaN |
| Accrued liabilities, other-Nonrelated Party | 1,735 | 25 | NaN | NaN |
| Accrued liabilities, other-Related Party | -1 | 6 | NaN | NaN |
| Accrued liabilities other | NaN | NaN | 583 | 646 |
| Accrued clinical liabilities-Nonrelated Party | 267 | NaN | NaN | NaN |
| Accrued clinical liabilities | NaN | -482 | -1,120 | 893 |
| Accrued clinical liabilities-Related Party | 216 | NaN | NaN | NaN |
| Accrued compensation | 261 | -510 | 866 | -1,464 |
| Lease obligation | NaN | -1 | 1 | NaN |
| Net cash used in operating activities | -6,932 | -17,977 | -11,331 | -20,157 |
| Proceeds from exercise of warrants | 21 | 1,265 | 120 | NaN |
| Proceeds from employee stock purchase plan note 10 | NaN | 0 | NaN | NaN |
| Taxes paid related to net share settlement of equity awards | NaN | 0 | NaN | NaN |
| Proceeds from private placement, net of issuance costs note 10-November2022Private Placement | NaN | 0 | NaN | NaN |
| Proceeds from registered direct offering, net of issuance costs-February2024Registered Direct Offering | NaN | 0 | NaN | NaN |
| Proceeds from june 2025 public offering, net of issuance costs note 7b-June2025Public Offering | NaN | -2 | -82 | 41,222 |
| Proceeds from june 2025 public offering exercise of overallotment option, net of issuance costs note 10b | NaN | 4,004 | NaN | NaN |
| Proceeds from june 2025 public offering exercise of overallotment option, net of issuance costs note 7b-June2025Public Offering | NaN | NaN | 4,004 | NaN |
| Receipt of 2024 svb convertible term loan second tranche note 6 and note 8 | NaN | 5,000 | NaN | NaN |
| Net cash provided by financing activities | 21 | 6,263 | 4,042 | 41,222 |
| Purchase of property and equipment | NaN | 3 | NaN | NaN |
| Loss on disposal of property and equipment | NaN | 1 | NaN | NaN |
| Realized gain on investments | NaN | 4 | NaN | NaN |
| Purchase of investments | NaN | 24,755 | NaN | NaN |
| Purchase of marketable securities | -18,508 | NaN | 15,404 | 4,260 |
| Maturities of investments | NaN | 30,866 | NaN | NaN |
| Maturities of marketable securities | -9,634 | NaN | 2,750 | 22,316 |
| Net cash provided by (used in) investing activities | 14,276 | 709 | -12,654 | 18,056 |
| Effect of exchange rate changes on cash | NaN | 4 | -1 | NaN |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 7,364 | -11,001 | -19,944 | 39,121 |
| Cash, cash equivalents and restricted cash at beginning of the period | 20,949 | 31,950 | 12,773 | NaN |
| Cash, cash equivalents and restricted cash at end of the period | 28,313 | 20,949 | 31,950 | NaN |
ACHIEVE LIFE SCIENCES, INC. (ACHV)
ACHIEVE LIFE SCIENCES, INC. (ACHV)